sb 203580 has been researched along with quizartinib in 2 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (quizartinib) | Trials (quizartinib) | Recent Studies (post-2010) (quizartinib) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 181 | 17 | 172 |
| Protein | Taxonomy | sb 203580 (IC50) | quizartinib (IC50) |
|---|---|---|---|
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | 0.042 | |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | 4.9 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.43 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 0.1024 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
2 other study(ies) available for sb 203580 and quizartinib
| Article | Year |
|---|---|
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |